Financial Perspectives Inc Trims Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Financial Perspectives Inc decreased its stake in Illumina, Inc. (NASDAQ:ILMN) by 35.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 392 shares of the life sciences company’s stock after selling 215 shares during the period. Financial Perspectives Inc’s holdings in Illumina were worth $52,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Bleakley Financial Group LLC acquired a new position in Illumina in the fourth quarter valued at $751,000. Zacks Investment Management acquired a new position in Illumina during the third quarter worth approximately $2,924,000. Van ECK Associates Corp lifted its stake in Illumina by 17.5% in the fourth quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock valued at $20,347,000 after buying an additional 22,718 shares during the last quarter. Strategic Financial Concepts LLC acquired a new stake in shares of Illumina in the fourth quarter valued at approximately $1,464,000. Finally, Freemont Management S.A. purchased a new position in shares of Illumina during the third quarter worth approximately $1,565,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Up 1.9 %

Illumina stock opened at $102.98 on Thursday. The firm has a market capitalization of $16.31 billion, a price-to-earnings ratio of -13.41, a price-to-earnings-growth ratio of 1.66 and a beta of 1.10. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a fifty-two week low of $99.33 and a fifty-two week high of $156.66. The stock’s fifty day moving average is $129.96 and its two-hundred day moving average is $134.41.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the subject of several research reports. UBS Group upped their price target on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and reduced their target price for the company from $177.00 to $140.00 in a report on Friday, February 7th. Barclays lowered Illumina from an “equal weight” rating to an “underweight” rating and lowered their price target for the stock from $130.00 to $100.00 in a report on Monday, February 10th. Citigroup cut Illumina from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. Finally, Morgan Stanley lowered their target price on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Illumina has an average rating of “Moderate Buy” and an average price target of $159.45.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.